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Abstract
Background: Abnormalities in heart rate during sleep linked to impaired neuro-cardiac modulation may provide new
information about physiological sleep signatures of depression. This study assessed the validity of an algorithm using
patterns of heart rate changes during sleep to discriminate between individuals with depression and healthy controls.
Methods: A heart rate profiling algorithm was modeled using machine-learning based on 1203 polysomnograms from
individuals with depression referred to a sleep clinic for the assessment of sleep abnormalities, including insomnia,
excessive daytime fatigue, and sleep-related breathing disturbances (n = 664) and mentally healthy controls (n = 529).
The final algorithm was tested on a distinct sample (n = 174) to categorize each individual as depressed or not
depressed. The resulting categorizations were compared to medical record diagnoses.
Results: The algorithm had an overall classification accuracy of 79.9% [sensitivity: 82.8, 95% CI (0.73–0.89), specificity:
77.0, 95% CI (0.67–0.85)]. The algorithm remained highly sensitive across subgroups stratified by age, sex, depression
severity, comorbid psychiatric illness, cardiovascular disease, and smoking status.
Conclusions: Sleep-derived heart rate patterns could act as an objective biomarker of depression, at least when it cooccurs with sleep disturbances, and may serve as a complimentary objective diagnostic tool. These findings highlight
the extent to which some autonomic functions are impaired in individuals with depression, which warrants further
investigation about potential underlying mechanisms.
Keywords: Heart rate variability, Autonomic nervous system, Major depressive disorder

Introduction
The search for an objective biomarker of depression
may lead to the development of complimentary clinical
tools to improve diagnosis and reveal novel therapeutic
targets. Changes in sleep physiology specifically linked to
depressive states have been proposed as a candidate. As
compared to healthy controls, people with depression
have increased sleep latency, more fragmented sleep, a
higher proportion of rapid eye movement (REM) sleep,
decreased REM latency, and, in some cases, decreased
amounts of slow-wave sleep (SWS) [1, 2]. However,
these abnormalities in sleep architecture are not specific
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to depressive states [3–5]. In parallel to efforts investigating sleep-related characteristics of depression, research focused on identifying depression biomarkers in
cardiovascular functions and related inflammatory processes offers promising findings, including increased
levels of peripheral vascular endothelial growth factor [6,
7], interleukin-6 [8], and C-reactive protein [9]. Furthermore, depression is often accompanied by increased
heart rate and reduced heart rate variability in both sleep
and wake states [10, 11]. Considering the growing body
of evidence suggesting that sleep disturbances may play
an active role in the pathophysiology of both cardiovascular dysfunctions and depression, we propose that
changes in heart rate during sleep may have potential as
an objective biomarker of depression.
Approximately 80% of individuals with a current major
depressive episode have co-occurring sleep difficulties
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[12], and sleep disruptions are known to be detrimental
to cardiovascular function. Sleep loss can contribute to
the emergence and/or worsening of cardiovascular ailments through changes in vascular functions [13], altered autonomic neuro-cardiac modulation [14], as well
as dysregulation of the hypothalamic-pituitary axis [15].
For instance, experimental studies have demonstrated
that sleep deprivation actively increases heart rate and
plasma levels of vascular endothelial cell activation
markers [13, 16]. Sleep deprivation also induces a shift
in the autonomic sympathovagal balance towards increased sympathetic cardiac modulation [14], which may
lead to alterations in cardiovascular regulatory processes.
Thus, sleep difficulties linked to depression may influence cardiovascular functions.
The pathophysiological changes in both cardiovascular
regulation and sleep patterns associated with depression are
likely to interact and alter heart rate dynamics during sleep,
thereby providing a relevant window to observe multisystemic biomarkers of depression. The cardiovascular signature of depression may be more prominent during sleep
since this state is shielded from several external influences
such as fluctuating daytime stress, physical activity, and
cognitive and emotional processing. Additionally, the reactivity of heart rate to endogenous dynamic changes
across the night (e.g., progression of sleep stages, interactions between homeostatic and circadian processes, and
changes in autonomic regulation) may yield more specific
indices of depression. Previous findings indeed suggest that
heart rate patterns across wake and sleep differ between
people with depression, anxiety disorders and healthy controls [17]. In a subsequent study, Iverson, Stampfer, et al.
(2002) reported an inter-rater agreement of 78% between
two experts who visually inspected heart rate patterns
across wake and sleep to determine the likelihood that an
individual has a psychiatric illness or not [18]. While promising, this approach is subjective and time consuming. Furthermore, these previous studies were mostly descriptive
and did not directly assess the validity of heart rate-based
classifications against diagnoses determined by standard
psychiatric assessment. Therefore, the current study aimed
to validate the diagnostic accuracy of an automated heart
rate profiling tool designed to capture changes across sleepwake states in order to objectively classify individuals according to depression status. To assess generalizability, we
also sought to compare classification performance across
different subgroups based on potential confounding factors,
including age, depression severity, psychiatric comorbidity,
psychoactive and cardiovascular medication use, cardiovascular disease, and smoking status.

Methods
An artificial intelligence based algorithm for automated
heart rate profiling was developed by an industry-based
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team of scientists and engineers (Medibio Limited, VIC,
Australia; Related patents: PCT/AU2016/050490 and
PCT/AU2018/050578). This algorithm was modeled
using machine-learning based on a sample of 1203 polysomnography recordings in people with clinician-based
depression diagnoses and healthy controls (training sample), and then tested in a distinct sample of 174 cases
(testing sample). Both the training and testing samples
were collated by the authors from retrospective and secondary databases as described below. This project was
approved by the Royal Ottawa Mental Health Centre
(ROMHC) Group Research Ethics Board and the
“Comité d’éthique de la recherche” of the Hôpital du
Sacré-Cœur de Montréal. Data from all other sites was
originally collected under approval from each site’s respective research ethics board. Preliminary analyses were
previously done by the authors and an independent biostatistician in parallel on a slightly smaller portion of this
sample for the purpose of CE marking (“Conformité
Européenne”; Certificate Registration Number: 532495
MR6). In the present article, a larger data sample was
used.
Cases
Training sample

Depression group The training sample contained 664
depression cases retrospectively collated from the
ROMHC Sleep Disorders Clinic polysomnography recordings. All of these individuals were referred by physicians to the Sleep Disorders Clinic due to a sleep
complaint such as insomnia, excessive daytime fatigue,
or sleep-related breathing disturbances. To be included
in this sample, all individuals had a diagnosis of a depressive syndrome documented in medical records (e.g.,
major depression, dysthymic disorder, depressive disorder not otherwise specified), and current depressive
symptoms on the Beck Depression Inventory (BDI-II
≥14) [19] at the time of polysomnography. A psychologist reviewed and classified all diagnostic information for
the purpose of this study. Table 1 provides the rates of
psychiatric comorbidities, but none of the individuals included in this sample had a diagnosis of bipolar disorder
or psychotic disorder.
Control group The training sample contained 529 healthy
control cases. This sample was pooled from the National
Sleep Research Resource (NSRR) [20–23] and the Montreal
Archive of Sleep Studies (MASS) [24] databases. Control
cases across both sites had no history of depression, anxiety
disorder, ADHD, neurological disorders or sleep disorders.
All cases from the MASS also scored asymptomatic on the
BDI (BDI-II < 14 or BDI-Short Form < 5).
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Table 1 Psychiatric comorbidities in the depression training and
testing samples
Training
Sample n (%)
Any psychiatric comorbidity

Testing
Sample n (%)

240 (36.1)

29 (33.3)

Anxiety disorder

175 (26.4)

21 (24.1)

Post-traumatic stress
disorder

3 (0.5)

0 (0.0)

Obsessive compulsive
disorder

15 (2.3)

4 (4.6)

Personality disorder

31 (4.7)

4 (4.6)

Substance abuse disorder

54 (8.1)

8 (9.2)

Intermittent explosive
disorder

0 (0.0)

1 (1.1)

Adjustment disorder

5 (0.8)

0 (0.0)

Eating disorder

13 (2.0)

0 (0.0)

Developmental disorder

33 (5.0)

5 (5.7)

Neurocognitive disorder

5 (0.8)

0 (0.0)

Testing sample

Depression group The depression cases used for the
final testing sample comprised a total of 87 individuals.
These cases were issued from the ROMHC Sleep Disorders Clinic database, but were all distinct from the cases
included in the training sample. Inclusion/exclusion criteria matched those of the training sample depression
group. Additionally, in order to limit the heterogeneity
of the sample, none of the patients included in this sample were taking antipsychotic medications or had a diagnosis of post-traumatic stress disorder. These additional
exclusion criteria were applied on the remaining sample
available for the testing phase.
Control group The control group for the testing sample
consisted of a total of 87 cases, all distinct from the control training sample. This sample was collated from four
sites: the MASS (51 cases), Western University’s Brain &
Mind Institute Sleep Research Laboratory (BMISRL; 20
cases), the “Centre d’étude des troubles du sommeil”
(CÉTS: 3 cases), and the ROMHC Sleep Disorders Clinic
(13 cases). Control cases sourced from the MASS,
BMISRL and CÉTS where healthy controls undergoing
standard polysomnography without any active intervention, and those from ROMHC Sleep Disorders Clinic
were patients referred by physicians for the assessment
of sleep abnormalities, including sleep-related breathing
disturbances. Control cases were selected from larger
datasets collected at each site in an effort to approximate
the age and sex distribution of the depression cases. Inclusion/exclusion criteria matched those of the training
sample control group. In addition, individuals from the
MASS, BMISRL and CÉTS were excluded if they were

using any medications known to interfere with sleep,
participated in regular night work, or had been on a
trans-meridian trip within 3 months prior to the polysomnography recording.
Polysomnographic recordings

Polysomnography recordings were conducted with similar procedures at all sites. This included scalp electroencephalogram (EEG) channels F3 and/or Fz, C3 and/or
Cz, and O1 and/or Oz, left and right electrooculogram
(EOG), electrocardiogram (ECG), chin and leg electromyogram (EMG), blood oxygen saturation via an oximeter probe on the finger, and respiratory effort via a
nasal thermistor, as well as thoracic and abdominal respiratory belts (MASS and ROMHC). Detailed acquisition parameters for each site are shown in Table 2. Sleep
stage scoring was manually performed by qualified
personnel in accordance with the clinical scoring guidelines established by the American Academy of Sleep
Medicine [25]. Across all sites, none of the scorers were
aware of the present study aims. The ECG signal was
processed to remove artefacts and extract inter-beat
interval (IBI) time series. In the testing set, all ECG recordings began at least 3 min prior to the first 30-s
epoch scored as sleep (mean recording durations before
and after sleep are reported in Table 3).
Algorithm training and testing procedures
Data division

While collating the data sets, the independent research
team used a random list generator to progressively select
10% of the data to put aside for the testing sample. The
remainder of the data was used for algorithm training.
Features

The heart rate profiling algorithm is based on a computational model of the relationship between mental state
and heart rate pattern characteristics. This integrated
multiple features of ECG dynamics including heart rate
and heart rate variability, as well as sleep stages scored
from the EEG.
Training

The Medibio team was provided with a sample of deidentified ECG and EEG data including healthy controls
and people with depression. Using this training sample,
a logistic regression with lasso regularization model was
employed to determine the optimal weight of each feature in order to attain the best classification of cases in
the depression and control groups. To avoid over-fitting
and over-optimistic results, a 10-fold cross-validation
procedure was performed using the training sample.
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Table 2 EEG and ECG acquisition parameters
Site

Hardware (Software)

Sampling Rate Timing of lights on/off
(Filters) [Hz]

ECG Location

ROMHC Sandman SD32 (Sandman 10.1; Natus
256 (none)
Medical Incorporated, San Carlos, CA, USA)

Mean habitual bedtime Top of shoulders
and wake time (up to
6:15–6:30 AM)

NSRR

Edentrace I or II (Edentec, Eden Prairie,
MN, USA)

128 (0.15)

Habitual sleep
schedule

MASS

Grass 15A54 (Harmonie Stellate System;
Natus Medical Incorporated,
San Carlos, CA, USA)

256 or 512
(0.3–100)

Mean habitual bedtime Left and right arms
and wake time

512 (0.1–220)

Mean habitual bedtime Below each clavicle
and wake time

256 (0.01–
100)

Mean habitual bedtime Below each clavicle
and wake time

BMISRL Embla Titanium (RemLogic; Natus
Medical Incorporated,
San Carlos, CA, USA)
CÉTS

Grass Model 12 (Harmonie Stellate
System; Natus Medical Incorporated,
San Carlos, CA, USA)

1) Below the midpoint of the right clavicle 2) Below
the left breast crease, in line with the midpoint of the
left clavicle (or below the midpoint of the left clavicle)

ROMHC Royal Ottawa Mental Health Centre, NSRR National Sleep Research Resource, MASS Montreal Archive of Sleep Studies, BMISRL Western University’s Brain &
Mind Institute Sleep Research Laboratory, CÉTS Centre d’étude des troubles du sommeil

Table 3 Sleep architecture and descriptive information for the testing sample
Variable

Control [x ̅ ± SD]b

MDD [x ̅ ± SD]b

U/χ2

p

n

87

87

–

–

Sex Distribution (%female)

55.2

58.6

.211

.646

Age (years)

43.3 ± 11.3

43.6 ± 10.5

3744.0

.903

AHI

1.7 ± 2.8

3.3 ± 5.0

2769.5

.002

BMI (kg/m2)

–

29.6 ± 6.8

–

–

BDI II Score

–

24.6 ± 9.0

–

–

Recording Time Before Sleep (min)

21.6 ± 15.0

40.2 ± 28.3

1882.5

.000

Recording Time After Sleep (min)

9.5 ± 28.9

4.6 ± 8.2

3398.5

.295

Total Recording Duration (min)

468.4 ± 35.6

474.2 ± 55.4

3550.5

.563

Total Sleep Time [TST (min)]

386.2 ± 43.8

355.6 ± 76.4

2891.0

.007

Sleep Efficiency (%)

87.7 ± 7.3

82.9 ± 14.3

3305.0

.149

Sleep Onset Latency (min)

13.6 ± 13.0

20.3 ± 18.7

2782.5

.003

REM Latency (min)a

98.6 ± 48.3

190.9 ± 106.6

1363.5

<.001

WASO (min)

55.1 ± 32.4

72.9 ± 62.2

3451.5

.316

N1 (min)

32.8 ± 18.8

66.4 ± 37.4

1617.5

<.001

N2 (min)

223.1 ± 47.9

207.3 ± 63.4

3151.0

.057

N3 (min)

54.7 ± 39.1

34.8 ± 33.7

2595.0

<.001

REM (min)

75.7 ± 25.5

47.1 ± 32.9

1788.0

<.001

N1 (% of TST)

8.7 ± 5.3

19.5 ± 11.5

1441.0

<.001

N2 (% of TST)

57.7 ± 10.5

58.0 ± 11.5

3760.0

.941

N3 (% of TST)

14.2 ± 10.1

9.7 ± 8.6

2758.0

.002

REM (% of TST)

19.4 ± 5.7

12.9 ± 9.0

1780.0

<.001

a

Eight individuals from the depression group had no REM sleep bDespite the use of a non-parametric test, the mean and standard deviation is reported for
better clarity
AHI Apnea-Hypopnea Index, BMI Body Mass Index, BDI Beck Depression Inventory, REM Rapid eye movement, WASO Wake after sleep-onset, N1 Non-REM 1, N2
Non-REM 2, N3 Non-REM 3
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Testing

Results

All files from the testing sample were carefully reprocessed
by the authors to ensure all formats and parameters were
exactly the same across files from all sites (e.g. using the
same labels and formats for derivations and sleep stage, excluding all signals except the ECG signals, down-sampling
the ECG signal to the lowest acquisition rate). These files
were identified by unique codes randomly allocated across
the mixed sample of depression and control cases. The final
algorithm was applied to this testing sample by the Medibio
team under blinded conditions. The resulting classifications
were sent back to the authors, who then conducted the independent validation analyses by comparing these to actual
medical record diagnoses.

Descriptive group characteristics

Statistical analyses

All statistical analyses were carried out using the Statistical Package for the Social Sciences (SPSS, version 22.0,
Armonk, NY: IBM Corp). For descriptive purposes, chisquare and Mann-Whitney U tests were performed in
the final testing sample to detect any significant differences between the control and depression groups in the
sex distribution, age, apnea/hypopnea index (AHI) and
sleep architecture.
As part of the validation analyses, the diagnostic classification based on the heart rate profiling algorithm was
compared to diagnostic information collated from medical
records. This was done using a confusion matrix [26], as
well as Cohen’s kappa statistic to determine ‘inter-rater
agreement’ between the two sets of classifications.
To evaluate how potential confounders may affect the
algorithm’s performance, the entire sample was stratified
by age and sex to compare kappa statistics across subgroups. The depression group was further stratified according to Body Mass Index [Underweight (< 18.5 kg/m2),
Normal (18.5 to 24.99 kg/m2), Overweight (25.0 to 29.99
kg/m2), and Obese (≥30 kg/m2) [27], psychotropic medication use, depression severity [Mild Depression (BDI- II:
14–19), Moderate Depression (BDI- II: 20–28), Severe Depression (BDI- II: 29–63)], the presence of psychiatric comorbidities, the presence of cardiovascular diseases or
related risk factors, current smoking status and polysomnographic variables found to differ between the control
and depression group (median split). The algorithm’s sensitivity was computed for each stratified subgroup.
Sleep architecture variables were compared for individuals who were incorrectly classified by the algorithm
(i.e. false positives and false negatives) with age and sexmatched subsets of correctly classified individuals (i.e.
true negatives and true positives). Furthermore, false
positive rates were compared across all control sites in
order to determine whether the use of different ECG
systems had an impact on the algorithm’s performance.

The training sample depression group was comprised of
72.9% females (mean age = 45.0 ± 15.7 years; age range
14 to 85 years). Of the overall training sample depression
group, 81.6% was taking psychotropic medication (see
Table 4 for details). The sex distribution of the training
sample control group was 55% female (mean age =
41.3 ± 18.5 years; age range 14 to 81 years). In the testing
sample, the depression group was comprised of 59% females (mean age = 43.6 ± 10.5 years; age range = 20 to 71
years), and the control group was comprised of 55% females (mean age = 43.3 ± 11.3 years; age range = 20 to 65
years). Further descriptive information for both groups
of the final testing sample is outlined in Table 3. There
were no significant age or sex differences between the
depression and control group. On average, total sleep
time was 30.6 min shorter in the depression group than
in the control group. Compared to the control group,
the depression group also had significantly longer sleep
Table 4 Psychotropic medications in the depression training
and testing samples
Training
sample n (%)

Testing
sample n (%)

542 (81.6)

69 (79.3)

SSRI

239 (36.0)

28 (32.2)

SNRI

190 (28.6)

19 (21.8)

Any psychotropic medication

TCA

39 (5.9)

6 (6.9)

NaSSA

43 (6.5)

2 (2.3)

MAOI

4 (0.6)

1 (1.1)

NRI/NARI

5 (0.8)

1 (1.1)

SARI

119 (17.9)

25 (28.7)

NDRI

89 (13.4)

12 (13.8)

RIMA

6 (0.9)

1 (1.1)

Other antidepressant

0 (0.0)

0 (0.0)

Antipsychotic

126 (19.0)

0 (0.0)

Mood stabilizer

71 (10.7)

8 (9.2)

Lithium

17 (2.6)

3 (3.4)

Melatonin agent

15 (2.3)

1 (1.1)

Benzodiazepine

96 (14.5)

8 (9.2)

Hypnotic/Sedative/Anxiolytic

123 (18.5)

2 (2.3)

Stimulant

38 (5.7)

4 (4.6)

Dopamine agonist

1 (0.2)

3 (3.4)

NMDA receptor antagonist

0 (0.0)

1 (1.1)

Acetylcholinesterase inhibitor

1 (0.2)

0 (0.0)

SSRI Selective Serotonin Reuptake Inhibitor, SNRI Serotonin-Norepinephrine
Reuptake Inhibitor, TCA Tricyclic Antidepressant, NaSSA Noradrenergic/Specific
Serotonergic Antidepressant, MAOI Monoamine Oxidase Inhibitor, NRI/NARI
Noradrenergic Reuptake Inhibitor, SARI Serotonin Antagonist and Reuptake
Inhibitor, NDRI Norepinephrine-Dopamine Reuptake Inhibitor, RIMA Reversible
Monoamine Oxidase Inhibitor
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onset latency and REM onset latency, as well as a lower
amount of REM sleep, both in absolute time and as a
percentage of total sleep time. Although the AHI
remained below the clinical threshold for both groups,
the depression group had a slightly but significantly
higher AHI than the control group.

Table 6 Classification agreement across age and sex groups in
the testing sample
Sex

Age Group

Validation of the heart rate profiling algorithm

The classification matrix is shown in Table 5. Overall,
the heart rate profiling algorithm had a classification accuracy of 79.9% [sensitivity: 82.8, 95% CI (0.73 to 0.89),
specificity: 77.0, 95% CI (0.67 to 0.85)]. There was a
moderate level of agreement with diagnoses derived
from medical records [κ = 0.60, 95% CI (0.48 to 0.72),
p < .001]. The degree of concordance between heart rate
based classifications and diagnoses documented from
medical records stratified by age and sex subgroups is
shown in Table 6. Cohen’s kappa reached at least the
moderate level in all subgroups, with similar concordance for males and females, and a higher concordance
for the 36–50 year old subgroup.
Sensitivity stratifications

Table 7 lists the algorithm’s sensitivity across subgroups of
the depression sample stratified by potential confounding
factors. There was no significant difference in the algorithm’s sensitivity across subgroups based on psychiatric
comorbidities, smoking status, the presence of cardiovascular disease and/or related risk factor, or the use of cardiovascular medication. Cardiovascular medication use
and comorbid medical disorders, including cardiovascular
diseases, are outlined for all groups in Additional file 1:
Table S1 and Additional file 2: Table S2, respectively. Conversely, the algorithm demonstrated significant differences
in sensitivity across subgroups stratified by psychotropic
medication use (χ2 (1) = 4.1, p < .050) and body mass index
(χ2(2) = 10.5, p = .005), with the highest sensitivities in the
Table 5 Confusion matrix of algorithm classification vs. actual
diagnosis
Actual Diagnosis
Depression

Control

Algorithm

Total

Depression 72a

20b

87

PPV: 78.3%

c

d

FOR: 18.3%

Control
Total

15

67

87

82

92

174

Sensitivity: 82.8% FPR: 23.0%
FNR: 17.2%
a

Specificity: 77.0%

True positives: Individuals with depression who were correctly classified
False positives: Healthy controls who were incorrectly classified as
depressedcFalse negatives: Individuals with depression who were incorrectly
classified as healthy controls dTrue negatives: Healthy controls who were
correctly classified
PPV Positive Predictive Value, FOR False Omission Rate, FNR False Negative
Rate, False Positive Rate
b

Group

Cohen’s kappa (κ)a

n

95% CI

p

Female

0.60

99

0.44 to 0.75

<.001

Male

0.60

75

0.42 to 0.78

<.001

18–35

0.56

47

0.32 to 0.80

<.001

36–50

0.72

71

0.54 to 0.89

<.001

51–71

0.41

56

0.17 to 0.65

.002

a

Concordance between heart rate-based classification and diagnoses
documented from medical records

subgroup taking psychotropic medication, and the subgroup with a BMI in the obese range.
False positives/false negatives

Fifteen of the 87 individuals with depression were incorrectly classified as controls (i.e. false negative: 60% female,
mean age ± SD = 43.2 ± 14.3 years; age range = 20 to 68
years). Compared to age and sex-matched depression
cases who were correctly classified, the false negative
group had significantly lower amounts of N1 sleep in absolute time (t (28) = − 4.4, p < .001), with an average of
30.1 (± 13.7) minutes of N1 sleep, as compared to 60.4 (±
22.8) minutes of N1 sleep in the true positive group. There
was no significant difference in AHI between false negatives (median = 0.6) and true positives (median = 2.7), U =
67.5, p = .061, nor between false positives (median = 0.7)
and true negatives (median = 0.5), U = 186.0, p = .703.
Twenty of the 87 healthy controls were incorrectly
classified as depressed (i.e. false positive: 55% female,
mean age ± SD = 44.3 ± 12.1 years; age range = 20 to 63
years). Compared to age and sex-matched controls who
were correctly classified, these false positives had significantly higher amounts of N1 (t (38) = 3.5, p = .001) and
REM (t (38) = − 2.1, p < .05) sleep, in absolute time. The
false positive group had an average of 45.6 (± 16.9) minutes of N1 sleep, and 65.4 (± 26.0) minutes of REM
sleep, whereas the true negative group had an average of
27.0 (± 17.0) minutes of N1 sleep, and 81.5 (± 22.5) minutes of REM sleep. There were no significant differences in the rates of false positives across the BMISRL,
CÉTS, MASS, and ROMHC sites (x2 (3) = 6.8, p = .080).

Discussion
This study demonstrates, for the first time, that changes in
heart rate across sleep-wake states may be valid physiological markers for the identification of depression in a
sample of people with sleep complaints. The heart rate
profiling algorithm classified individuals with an accuracy
of 79.9%. Specifically, the algorithm was able to detect
82.8% of the depression cases, and rule out 77.0% of
healthy controls (these results are in line with the preliminary analyses conducted for CE marking). In comparison,
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Table 7 Algorithm sensitivity across the testing sample depression group stratified by potential confounding factors
Body Mass Index

Stratification

Sensitivity (%)a

n

χ 2(df)

p

Normal

61.9

21

10.5 (2)

.005

Overweight

83.3

36

4.1 (1)

<.050

0.2 (2)

.927

1.5 (1)

.229

0.0 (1)

.838

0.0 (1)

.982

0.0 (1)

.930

2.2 (1)

.141

0.0 (1)

.891

0.7 (1)

.390

4.1 (1)

<.050

Obese

96.7

30

Psychotropic Medication Use

Yes

87.0

69

No

66.7

18

Depression Severity

Mild

83.9

31

Psychiatric Comorbidity

Cardiovascular Disease or Related Risk Factor

Cardiovascular Medication Use

Smoking Status

AHI

Sleep Onset Latency (min)

REM Onset Latency (min)

%REM

Moderate

80.6

31

Severe

84.0

25

Yes

75.9

29

No

86.2

58

Yes

83.9

31

No

82.1

56

Yes

82.6

23

No

82.8

64

Non-Smoker

82.5

63

Current Smoker

83.3

24

< 5

79.7

69

≥5

94.4

18

≤ 15

82.2

45

> 15

83.3

42

≤ 164

80.0

40

> 164

87.2

39

≤ 13

90.9

44

> 13

74.4

43

a

The algorithm’s ability to accurately detect cases of depression (i.e. true positive rate)
AHI Apnea-Hypopnea Index, REM Rapid eye movement

the detection rate of depression amongst primary care
practitioners is thought to be approximately 47% [28].
Considering that the algorithm performed substantially
well in comparison to standard diagnostic procedures, this
tool may serve as an objective, adjunctive measure to assist in depression diagnosis and monitoring. Subsequent
studies should evaluate whether currently accessible ambulatory ECG devices could be used to track sleep-derived
profiles indicative of depression. From this perspective,
the algorithm could potentially serve as a non-invasive
and low-cost tool. The combined use of a classification instrument with clinician-based diagnosis may improve
diagnostic accuracy and means of patient monitoring.
Depressive disorders are associated with sympathetic
hyperactivity and reduced cardiac vagal control, which
increases the risk of cardiovascular disease. Considering the associations between depression and inflammation [8, 9], as well as the role of the vagus nerve
in mediating the cholinergic anti-inflammatory pathway [29, 30], it has been suggested that this autonomic imbalance may occur via the effects of pro-

inflammatory cytokines on the central autonomic network [31]. The accuracy of this sleep ECG tool in detecting depression simply based on heart rate profiles
during sleep highlights the extent to which autonomic
neuro-cardiac regulation is dysfunctional in individuals with depression and sleep complaints. Further investigation is warranted to identify the specific
physiological mechanisms of depression, alone or in
combination with sleep disturbances, that underlie the
abnormal profiles of heart rate dynamics during sleep.
Given the increased risk of cardiac morbidity and
mortality in these individuals, and the fact that increased heart rate and reduced heart rate variability
are known to increase the risk of cardiac morbidity
and mortality [32–34], this also emphasizes the need
to assess whether chronic autonomic dysfunctions
during sleep may, over time, contribute to poor
health outcomes in people with depression. Prospective work is required to clarify how heart rate changes
during sleep may relate to cardiovascular events and
related risks factors in people with depression.
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Trait versus state marker

Preliminary studies of heart rate recordings during wake
have shown that deviant heart rate patterns progressively
normalize with effective antidepressant medication treatment of depression [35], and electroconvulsive therapy
[36]. This reinforces the notion that the observed atypical heart rate patterns are manifestations of the physiological changes associated with depressive states
resulting from autonomic nervous system dysfunction
[37]. Whether heart rate profiles during sleep may be
sensitive to changes in depressive states remains to be
more thoroughly investigated. If further studies are able
to establish that heart rate profiles during sleep
normalize following successful treatment, the heart rate
profiling algorithm used in this study may provide a
helpful tool to objectively monitor treatment effectiveness over time.
Sensitivity stratifications

The algorithm performed well across subgroups stratified based on sex, age, depression severity, comorbid
psychiatric illness, comorbid cardiovascular disease and
related risk factors, and smoking status. This suggests
that the algorithm’s sensitivity to depression is
generalizable across individuals with several potential
confounding factors.
The algorithm had a significantly higher sensitivity in
individuals with a BMI in the obese range and in those
with elevated AHI, two factors often interconnected [38]
and known to interact with cardiovascular functions.
One the one hand, obesity is linked to a clear autonomic
imbalance, with elevated sympathetic activity and lower
vagal activity [39–41]. On the other hand, sleep-related
breathing disorders are associated with a hyperactivation
of the sympathetic nervous system due to intermittent
hypoxia and sleep fragmentation [42]. Overall, cardiovascular alterations resulting from obesity and/or sleeprelated breathing disturbances may have led to a higher
likelihood of detection by the algorithm. Nevertheless,
the algorithm’s sensitivity remained above 61 and 83% in
people with a BMI within the normal and overweight
ranges respectively, and remained above 79% in those
with an AHI below 5. Even if the depression group had,
on average, higher BMI and AHI than the control group,
the ability of the algorithm to efficiently detect depression cases amongst individuals with low BMI and AHI
suggests that the algorithm’s sensitivity to depression
was not solely based on indirect effects of elevated BMI
or AHI on the ECG.
The depression subgroup with psychotropic medication use also had a higher rate of correct detection based
on the heart rate profiling algorithm. This could be simply due to differences in statistical power, as only 20.7%
of the depression group was free of psychotropic
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medication use at the time of polysomnography. However, the use of antidepressants is associated with reductions in heart rate variability, and prospective studies are
required to determine if these medications could possibly lead to better detection by the algorithm. Statistical
power issues may also apply for the high detection rate
in the 36–50 year age group, since this age bracket was
over-represented. As such, the sensitivity of the algorithm should be further investigated in individuals who
do not use psychotropic drugs, as well as across varying
age groups. Various profiles of sleep disturbances have
been found in individuals with depression, such as shortened REM onset latency, increased amounts of REM
sleep as a percentage of total sleep time, increased REM
density, and lengthened sleep onset latency [2, 4]. However, these abnormalities in REM sleep were not observed in our sample, possibly due to the use of
antidepressant medication. However, in subgroups of patients with different sleep patterns, namely those with
longer or shorter sleep, and longer or shorter REM onset
latencies, the algorithm’s sensitivity remained consistent.
Of note, the algorithm had a higher sensitivity in individuals with a lower proportion of REM sleep. Considering the higher classification sensitivity observed in those
taking antidepressant medications, which are known to
actively suppress REM sleep, this is likely to be related
to the higher sensitivity found in the subgroup of medicated individuals. Interestingly, while the overall depression group had significantly higher amounts of N1 sleep
on average than the controls, the subgroup of controls
incorrectly classified as depression cases (i.e. false positives) also had high N1 amounts, and the depression
cases incorrectly classified as controls (i.e. false negatives) had low N1 amounts. From this perspective, heart
rate changes during shallow sleep may be an especially
important feature used by the algorithm for the identification of depression.
Overall, the new biomarker developed herein persisted at a high level, independently of global
differences in sleep architecture. Considering that abnormalities in standard EEG-based sleep measures are
known to be poorly specific to depressive states [3–5],
this multi-systemic biomarker tapping on dynamic
changes in both brain and heart activity, may be more
promising to distinguish between different mental
illnesses.

Limitations
We acknowledge several limitations in this study. Due to
intellectual property rights, the specific content of the
algorithm cannot be disclosed. The control group data
was obtained from four different sites with slightly differing EEG and ECG acquisition parameters, while the
depression group data was sourced from one site.
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However, the sourcing of data from multiple sites allowed
testing the algorithm on a larger and more diverse sample,
which highlights its robustness and generalizability. Also,
there were no significant differences in the false positive
rate across different sites. The depression group consisted
of individuals with sleep complaints who were referred to
a specialized sleep disorders clinic, but only a portion of
the control group had sleep complaints and was referred
to a sleep clinic. As such, the large majority of depression
cases had significant sleep problems, including sleeprelated breathing disorders, which may influence heart
rate patterns. However, the average AHI amongst both
testing groups were below the clinical cut-offs for sleep
apnea. Although sleep disturbances often co-occur with
depression, the sample used in the present study may not
be representative of the general depression population.
Further work is required to decipher the relative contribution of depression and sleep abnormalities, including
breathing disturbances, to the abnormal heart profiles detected by the algorithm. Importantly, working with this
sample allowed us to establish that the algorithm classification remained accurate across a wide range of sleep profiles. Moreover, due to the effects of psychotropic
medication on cardiac activity, the use of psychotropic
medication in the majority of our sample could possibly
have facilitated better detection of depression by the algorithm. Therefore, the algorithm’s performance must be investigated in a larger sample of individuals free of
psychotropic medication use. Due to the retrospective nature of this study, it was not possible to ascertain whether
individuals from the depression group and part of the
control group had traveled across time zones or worked
night shifts close to the time of the sleep recordings.

Conclusions
The current study validated a novel diagnostic classification tool based on an objective, multi-systemic biomarker of depression in a clinical sample of individuals
with depression and sleep complaints. This tool, based
on heart rate changes under the influence of autonomic
regulation during sleep, was found to be highly
generalizable across several potential confounding variables, as well as across differing ECG/EEG acquisition
systems. In addition to providing an improved biological
underpinning for the diagnosis of depression, this could
possibly offer supplemental information to psychiatric
clinical assessment, and objective measures for early
screening. Moreover, the use of distinct physiological
variables as biomarkers of depression may help
emphasize the interactions between mental and physical
health. This may contribute to reducing the stigma associated with depression, lifting some social barriers to
accessing psychiatric treatment, and allowing for more
holistic patient care.
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